BioSpace News Archive

Researchers at Arthritis Research Canada have found that people with osteoarthritis who started taking tramadol, an opioid pain medication, were at a 20-50 per cent greater risk of mortality, 70 per cent greater risk of blood clots, and 40-60 per cent greater risk of hip fractures when compared to people who started using drugs like aspirin or ibuprofen.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that new clinical data from its OCS™ Heart and OCS™ Lung clinical trials will be presented at the upcoming International Society of Heart and Lung Transplantation (ISHLT) 2022 Annual Meeting.

Protagonist Therapeutics, Inc. reported that on April 18, 2022, it issued inducement awards to three recently hired employees in accordance with the terms of their employment offer letters.

RxSight, Inc. today announced that its Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens ® (LAL ® ), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various surgeon presentations at the annual meeting of the American Society of Cataract and Refractive Annual Meeting.

Today, Stimwave Technologies announced the level-1 FREEDOM clinical trial series launch.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022.

Amcor plc will announce its year to date results for the nine months ended 31 March 2022 after the US market closes on Tuesday 3 May 2021.

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies.

Virtual Incision Corporation today announced the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement to complete the final stage of its clinical study analyzing the MIRA ® Platform in bowel resection procedures.

eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced the promotion of Michael Curtis, Ph.D., to Chief Executive Officer (CEO).